18 Best Dividend Stocks for Passive Income — Ranked for 2026

3. Johnson & Johnson (JNJ) - The Healthcare Dividend Aristocrat

Johnson & Johnson claims the third spot in our rankings as a testament to the power of diversified healthcare businesses in generating consistent dividend income across multiple economic cycles and market conditions. As a member of the prestigious Dividend Aristocrats club with 61 consecutive years of dividend increases, J&J represents the gold standard of dividend reliability and has proven its ability to navigate patent cliffs, regulatory challenges, and competitive pressures while maintaining uninterrupted dividend growth. The company's three-pillar business model, encompassing pharmaceuticals, medical devices, and consumer products, provides natural diversification that reduces dependence on any single product or market segment while creating multiple avenues for cash flow generation. J&J's pharmaceutical division, featuring blockbuster drugs like Stelara, Darzalex, and Imbruvica, generates substantial cash flows with high margins that support the dividend while funding continued research and development investments in innovative therapies. The medical device segment benefits from demographic trends including aging populations and increased healthcare utilization, providing steady growth in markets ranging from surgical instruments to orthopedic implants. Despite recent challenges including legal settlements and spin-off activities, J&J's fundamental business strength, conservative payout ratio of approximately 45%, and commitment to maintaining its dividend aristocrat status make it an essential holding for income-focused portfolios seeking stability and predictable growth.